References
- Iqbal MM, Rahman A, Husain Z, et al. Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry. 2003;15(1):33–48.
- Kane JM, Correll CU. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry. 2010;71(9):1115–1124.
- McEvoy JP, Lieberman JA, Stroup TS, for the CATIE Investigators, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163(4):600–610.
- Nakajima S, Takeuchi H, Fervaha G, et al. Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data. Schizophr Res. 2015;161(2-3):429–433.
- Ingimarsson O, MacCabe JH, Haraldsson M, et al. Clozapine treatment and discontinuation in Iceland: a national longitudinal study using electronic patient records. Nord J Psychiatry. 2016;70(6):450–455.
- Meltzer HY, Alphs L, Green AI, International Suicide Prevention Trial Study Group, et al. Clozapine treatment for suicidality in schizophrenia: International suicide prevention trial (intersept). Arch Gen Psychiatry. 2003;60(1):82–91.
- Krakowski MI, Czobor P, Citrome L, et al. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2006;63(6):622–629.
- Brunette MF, Drake RE, Xie H, et al. Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr Bull. 2006;32(4):637–643.
- Lin CH, Chen FC, Chan HY, et al. Time to rehospitalization in patients with schizophrenia receiving long-acting injectable antipsychotics or oral antipsychotics. Int J Neuropsychopharmacol. 2019;22(9):541–547.
- Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620–627.
- Hayes RD, Downs J, Chang CK, et al. The effect of clozapine on premature mortality: an assessment of clinical monitoring and other potential confounders. Schizophr Bull. 2015;41(3):644–655.
- Grover S, Balachander S, Chakarabarti S, et al. Prescription practices and attitude of psychiatrists towards clozapine: a survey of psychiatrists from India. Asian J Psychiatr. 2015;18:57–65.
- Grover S, Hazari N, Chakrabarti S, et al. Delay in initiation of clozapine: a retrospective study from a tertiary care hospital in North India. Psychiatry Res. 2015;226(1):181–185.
- Gee SH, Shergill SS, Taylor DM. Patient attitudes to clozapine initiation. Int Clin Psychopharmacol. 2017;32(6):337–342.
- Angermeyer MC, Löffler W, Müller P, et al. Patients' and relatives' assessment of clozapine treatment. Psychol Med. 2001;31(3):509–517.
- Dickson RA, Williams R, Dalby JT. The clozapine experience from a family perspective. Can J Psychiatry. 1995;40(10):627–629.
- Waserman J, Criollo M. Subjective experiences of clozapine treatment by patients with chronic schizophrenia. Psychiatr Serv. 2000;51(5):666–668.
- Taylor D, Shapland L, Laverick G, et al. Clozapine - a survey of patient perceptions. Psychiatr Bull. 2000;24(12):450–452.
- Lewis SW, Barnes TR, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull. 2006;32(4):715–723.
- Hodge K, Jespersen S. Side-effects and treatment with clozapine: a comparison between the views of consumers and their clinicians. Int J Ment Health Nurs. 2008;17(1):2–8.
- Li Q, Xiang YT, Su YA, et al. Clozapine in schizophrenia and its association with treatment satisfaction and quality of life: findings of the three national surveys on use of psychotropic medications in China (2002-2012). Schizophr Res. 2015;168(1-2):523–529.
- Kay SR, Fiszbein A, Opler A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276.
- Andreasen NC, Carpenter WT, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441–449.
- Busner J, Targum SD. The Clinical Global Impressions Scale. Psychiatry (Edgmont). 2007;4(7):28–37.
- Ní Dhubhlaing C, Young A, Sahm LJ. Impact of pharmacist counselling on clozapine knowledge. Schizophr Res Treatment. 2017;2017:1–8.